<SEC-DOCUMENT>0001193125-25-004062.txt : 20250110
<SEC-HEADER>0001193125-25-004062.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110070018
ACCESSION NUMBER:		0001193125-25-004062
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Seres Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001609809
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				274326290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37465
		FILM NUMBER:		25520338

	BUSINESS ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617 945 9626

	MAIL ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Seres Health, Inc.
		DATE OF NAME CHANGE:	20140603
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d925391d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mcrb="http://serestherapeutics.com/20250109" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-297">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-01-09_to_2025-01-09">0001609809</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="mcrb-20250109.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-01-09_to_2025-01-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001609809</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-09</xbrli:startDate> <xbrli:endDate>2025-01-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-308">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt:datemonthdayyearen" id="ixv-309">January&#160;9, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-310">SERES THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:stateprovnameen" id="ixv-311">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-312">001-37465</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-313">27-4326290</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-314">101 Cambridgepark Drive</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-315">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-316">MA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-317">02140</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-318">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-319">945-9626</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-320">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-321">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-322">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-323">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-324">Common stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-325">MCRB</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:exchnameen" id="ixv-326">The Nasdaq Stock Market LLC</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Nasdaq Global Select Market)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-327">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;2.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2025, Seres Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing, among other things, the Company&#8217;s preliminary cash and cash equivalents as of the fiscal year ended December&#160;31, 2024, new translational biomarker results from the <span style="white-space:nowrap">SER-155</span> Phase 1b clinical study, and corporate updates. The full text of the press release issued by the Company is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> (this &#8220;Current Report&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, on January&#160;9, 2025, the Company announced translational biomarker results from exploratory endpoints in its <span style="white-space:nowrap">SER-155</span> Phase 1b placebo-controlled study in patients undergoing allogeneic hematopoietic stem cell transplantation (&#8220;allo-HSCT&#8221;). Following <span style="white-space:nowrap">SER-155</span> administration, there was a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and a positive impact on biomarkers of systemic inflammation and immune homeostasis, in both cases as compared to placebo. The biomarker data are consistent with <span style="white-space:nowrap">SER-155&#8217;s</span> mechanism of action and the Company believes provide further evidence of the potential of <span style="white-space:nowrap">SER-155</span> in reducing bloodstream infections through the promotion of epithelial barrier integrity, which may lead to a reduced risk of the translocation of bacteria from the gastrointestinal tract into the bloodstream. The Company also believes that the lower concentrations of plasma biomarkers of systemic inflammation and immune homeostasis observed following <span style="white-space:nowrap">SER-155</span> dosing reinforce the positive impact in allo-HSCT patients in this trial. In December 2024, the US Food and Drug Administration (&#8220;FDA&#8221;) granted Breakthrough Therapy designation to <span style="white-space:nowrap">SER-155</span> for reduction of bloodstream infections in adults undergoing allo-HSCT. The Company submitted a Briefing Book in support of its planned interaction with FDA on a potential next registrational study of <span style="white-space:nowrap">SER-155</span> in allo-HSCT and expects feedback from the agency in the first quarter of 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company announced that, based on preliminary financial results, it had $31&#160;million in cash and cash equivalents (unaudited) as of December&#160;31, 2024. This preliminary estimate is based on preliminary unaudited information and the Company&#8217;s current estimate of its results for the year ended December&#160;31, 2024, and remains subject to change based on the completion of closing and review procedures and the execution of the Company&#8217;s internal control over financial reporting. The Company&#8217;s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on existing cash, the projected installment payments to be received from Nestl&#233; Health Science in January and July 2025 (totaling approximately $75 million) related to the VOWST sale, transaction-related obligations and current operating plans (including the planned investment in preparatory activities for the next <span style="white-space:nowrap">SER-155</span> study), the Company expects to fund operations into the first quarter of 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: our anticipated financial performance, including cash and cash equivalents, for any period of time, including for the year ended December&#160;31, 2024; the timing and results of our clinical studies and data readouts; our clinical development plans; the potential market for <span style="white-space:nowrap">SER-155</span> and other product candidates, if approved; the projected cash runway; and other statements which are not historical fact. These forward-looking statements are based on management&#8217;s current expectations. These statements </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption &#8220;Risk Factors&#8221; in our Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), on November&#160;13, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management&#8217;s estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Disclosure Advisory </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preliminary cash and cash equivalents and projected cash runway information represents information available to the Company&#8217;s management through the date hereof. Actual results for the year ended December&#160;31, 2024 will depend on the completion of <span style="white-space:nowrap">quarter-end</span> accounting procedures and adjustments, including the completion of the Company&#8217;s financial statements and the subsequent occurrence or identification of events prior to the filing of our financial results for the relevant period with the SEC. The estimated preliminary financial results have not been audited or reviewed by the Company&#8217;s independent registered public accounting firm. These estimates should not be viewed as a substitute for the Company&#8217;s full interim or annual financial statements. Accordingly, you should not place undue reliance on this preliminary data. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following Exhibit 99.1 relates to Item 2.02, and shall be deemed to be furnished, and not filed: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d925391dex991.htm">Seres Therapeutics, Inc. Translational Biomarker Results from <span style="white-space:nowrap">SER-155</span> Phase 1b Clinical Study Press Release as of January&#160;9, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">SIGNATURES</span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: January&#160;10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">SERES THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. DesRosier</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Thomas J. DesRosier</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Legal Officer and Executive Vice President</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d925391dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Seres Therapeutics Announces New Translational Biomarker Results from <FONT STYLE="white-space:nowrap">SER-155</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 1b Clinical Study and Provides Corporate Updates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>New <FONT STYLE="white-space:nowrap">SER-155</FONT> Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation
(allo-HSCT) recipients demonstrate that <FONT STYLE="white-space:nowrap">SER-155</FONT> promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres&#146; live
biotherapeutics to target inflammatory and immune diseases </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">SER-155</FONT> clinical results
accepted for 2025 TANDEM Meeting oral presentation in Best Abstracts in Infectious Diseases </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>New
<FONT STYLE="white-space:nowrap">SER-155</FONT> payer research underscores unmet need and supports potential as a substantial commercial opportunity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cash runway extended into Q1 2026 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass.&#151;January 9, 2025&#151; Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today
announced new translational biomarker results for exploratory endpoints from its <FONT STYLE="white-space:nowrap">SER-155</FONT> Phase 1b placebo-controlled study in patients undergoing allogenic stem cell transplantation (allo-HSCT). Following <FONT
STYLE="white-space:nowrap">SER-155</FONT> administration, there was a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and a positive impact on biomarkers of systemic inflammation and
immune homeostasis, in both cases as compared to placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These results support the previously announced clinical data demonstrating that <FONT
STYLE="white-space:nowrap">SER-155</FONT> was associated with a significant reduction in bloodstream infections (BSIs) (reflecting a 77% relative risk reduction). The biomarker data are consistent with <FONT STYLE="white-space:nowrap">SER-155</FONT>
mechanism of action and provide further evidence of the potential of <FONT STYLE="white-space:nowrap">SER-155</FONT> to reduce BSIs through the promotion of epithelial barrier integrity, which reduces the likelihood of the translocation of bacteria
from the gastrointestinal tract into the bloodstream. The lower concentrations of plasma biomarkers of systemic inflammation, and changes in immune homeostasis observed following <FONT STYLE="white-space:nowrap">SER-155</FONT> dosing reinforce the
positive impact in allo-HSCT patients. These data also support the potential role for Seres&#146; live biotherapeutic platform to provide clinical benefit to patients with inflammatory and immune diseases, such as IBD, including ulcerative colitis
and Crohn&#146;s disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wendy Garrett, M.D. Ph.D., Professor of Immunology and Infectious Diseases, Department of Immunology&nbsp;&amp; Infectious
Diseases, Harvard T.H. Chan School of Public Health, Harvard University, commented, &#147;The <FONT STYLE="white-space:nowrap">SER-155</FONT> translational biomarker data, combined with&nbsp;the&nbsp;promising clinical results demonstrating an
impressive reduction in bloodstream infection rates, provide strong biological evidence supporting Seres&#146; live biotherapeutic candidates as a novel&nbsp;potential&nbsp;therapeutic approach to improve epithelial barrier integrity and to
positively modulate multiple inflammatory pathways. These data support potential opportunities&nbsp;for live biotherapeutics, beyond infection, in inflammatory and immune diseases.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Corporate Updates </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Seres&#146; <FONT STYLE="white-space:nowrap">SER-155</FONT> Phase 1b clinical study results have been accepted
for an oral presentation in the Best Abstracts in Infectious Diseases track and the related drug pharmacology results have been accepted as a poster presentation at the February 2025 TANDEM Meeting, a multidisciplinary event highlighting the latest
research and breakthroughs in the evolving field of hematopoietic cell transplantation, cellular therapy and gene therapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Market research recently completed by the Company with US healthcare professionals (HCPs) and payers confirmed
the view that there is a high unmet need to prevent BSIs in allo-HSCT patients and a desire for better prophylactic options, suggesting a strong value proposition for <FONT STYLE="white-space:nowrap">SER-155.&nbsp;Both</FONT> HCPs and payers
indicated an awareness of the high clinical burden of BSIs, driven by high frequency of occurrences and poor associated outcomes. Both groups cited a lack of efficacious prophylactic therapies and expressed significant ongoing concerns around the
risk of BSIs, febrile neutropenia, sepsis, and antibiotic-resistant infections. Specific to <FONT STYLE="white-space:nowrap">SER-155,</FONT> the proposed risk reduction of BSIs and related endpoints were seen as clinically meaningful and supportive
of a strong value proposition. Payers shared an expectation that coverage of <FONT STYLE="white-space:nowrap">SER-155</FONT> would be under the outpatient pharmacy benefit, given its oral administration, which would allow for dosing outside of the
inpatient hospital setting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In December 2024, the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to <FONT
STYLE="white-space:nowrap">SER-155</FONT> for reduction of bloodstream infections in adults undergoing allo-HSCT. The Company submitted a Briefing Book in support of its planned interaction with FDA on a potential next registrational study of <FONT
STYLE="white-space:nowrap">SER-155</FONT> in allo-HSCT and expects feedback from the agency this quarter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company has continued implementing actions to extend its projected cash runway. As of December&nbsp;31, 2024,
Seres had approximately $31&nbsp;million in cash and cash equivalents (unaudited figure). Based on existing cash, the projected installment payments to be received from Nestl&eacute; Health Science in January and July 2025 (totaling approximately
$75 million) related to the VOWST sale, transaction-related obligations and current operating plans (including the planned investment in preparatory activities for the next <FONT STYLE="white-space:nowrap">SER-155</FONT> study), the Company expects
to fund operations into the first quarter of 2026. The Company continues to evaluate cash preservation actions and timing of investments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We continue to make progress in advancing clinical development of <FONT STYLE="white-space:nowrap">SER-155</FONT> in allo-HSCT. Having received
Breakthrough Therapy designation for <FONT STYLE="white-space:nowrap">SER-155</FONT> from the FDA in December, our team recently submitted a Briefing Book, and we expect to engage with the agency later this quarter on our development plans,
including our proposal to conduct a single registrational study for efficacy to support product approval in allo-HSCT,&#148; said Eric Shaff, President and Chief Executive Officer of Seres Therapeutics. &#147;We believe the medical and commercial
opportunity for <FONT STYLE="white-space:nowrap">SER-155</FONT> is substantial, and recent payer research suggests that a product with a similar clinical profile to the results we have observed would have a robust value proposition for patients,
providers and payers. We are actively engaging with external parties as we seek a partner to provide financial resources and other capabilities to maximize the <FONT STYLE="white-space:nowrap">SER-155</FONT> opportunity.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Shaff continued, &#147;The new <FONT STYLE="white-space:nowrap">SER-155</FONT> biomarker data
expand upon our previously reported clinical results and strengthen our mechanistic understanding of the potential of <FONT STYLE="white-space:nowrap">SER-155</FONT> in preventing bacteremia and corresponding BSIs in allo-HSCT and potentially other
medically vulnerable patient groups. We believe the gut barrier integrity data enhanced by the observed positive impact on biomarkers of systemic inflammation and immune homeostasis, also support the potential for Seres&#146; live biotherapeutic
candidates to be developed as treatments for serious inflammatory diseases, such as IBD, including ulcerative colitis and Crohn&#146;s disease. Underpinned by the promising clinical data we have generated and the wide range of diseases that could be
amenable to our biotherapeutic candidates, we intend to seek partnerships to further evaluate these substantial opportunities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT
STYLE="white-space:nowrap">SER-155</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SER-155</FONT> is an investigational, oral, live biotherapeutic designed to
decolonize GI pathogens, improve epithelial barrier integrity, and induce immune tolerance to prevent bacterial bloodstream and antimicrobial resistant (AMR) infections, as well as other pathogen associated negative clinical outcomes, in patients
undergoing allo-HSCT for the treatment of hematological malignancies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SER-155</FONT> has been evaluated in a Phase 1b
placebo-controlled study in patients undergoing allo-HSCT, which demonstrated a significant reduction in both BSIs and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia. <FONT STYLE="white-space:nowrap">SER-155</FONT>
has received Breakthrough Therapy designation for the reduction of BSIs and Fast Track designation for reducing the risk of infection and GvHD, in both cases in patients undergoing HSCT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Seres Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seres Therapeutics,
Inc.&nbsp;(Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> orally administered microbiome therapeutic, which was sold to Nestl&eacute; Health Science in&nbsp;September 2024. The Company is
developing <FONT STYLE="white-space:nowrap">SER-155,</FONT> which has received both Breakthrough Therapy and Fast Track designation, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared
to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. <FONT STYLE="white-space:nowrap">SER-155</FONT> and the Company&#146;s other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured
from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate <FONT STYLE="white-space:nowrap">SER-155</FONT> and other cultivated
live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, <FONT STYLE="white-space:nowrap">CAR-T</FONT> recipients, individuals with chronic liver disease,
solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit <U>www.serestherapeutics.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in
this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: our anticipated financial performance, including cash and cash equivalents, for any period of time,
including for the year ended December&nbsp;31, 2024; the timing and results of our clinical studies and data readouts; our clinical development plans; the anticipated timing of communications with or feedback from the FDA; the impact, value or
potential benefits of Breakthrough Therapy designation, Fast Track designation or any other regulatory designations; our ability to secure a partnership and/or generate additional capital; the potential market and commercial opportunity for <FONT
STYLE="white-space:nowrap">SER-155</FONT> and other product candidates, if approved; projected cash runway; and other statements which are not historical fact. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on management&#146;s current expectations. These statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements, including, but not limited to, the following: (1)&nbsp;we have incurred significant losses, are not currently profitable and may never become profitable; (2)&nbsp;our need for additional funding; (3)&nbsp;our history of operating losses;
(4)&nbsp;our novel approach to therapeutic intervention; (5)&nbsp;our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (6)&nbsp;the competition we will face; (7)&nbsp;our ability to protect our
intellectual property; (8)&nbsp;our ability to retain key personnel and to manage our growth; (9)&nbsp;the effect of the VOWST sale on our ability to retain and hire key personnel and maintain relationships with our customers, suppliers,
advertisers, partners and others with whom we do business, or on our operating results and businesses generally; (10)&nbsp;the risks associated with the disruption of management&#146;s attention from ongoing business operations due to the obligation
to provide transition services; (11)&nbsp;our failure to receive the installment payments or the milestone payments in the future; (12)&nbsp;the uncertainty of impact of the 50/50 profit and loss sharing arrangement on our reported results and
liquidity; and (13)&nbsp;we may not be able to realize the anticipated benefits of the VOWST sale. These and other important factors discussed under the caption &#147;Risk Factors&#148; in our Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the Securities and Exchange Commission (SEC), on November&nbsp;13, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such forward-looking statements represent management&#146;s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Disclosure Advisory </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preliminary cash and
cash equivalents and projected cash runway information represents information available to the Company&#146;s management through the date hereof. Actual results for the year ended December&nbsp;31, 2024 will depend on the completion of <FONT
STYLE="white-space:nowrap">quarter-end</FONT> accounting procedures and adjustments, including the completion of the Company&#146;s financial statements and the subsequent occurrence or identification of events prior to the filing of our financial
results for the relevant period with the SEC. The estimated preliminary financial results have not been audited or reviewed by the Company&#146;s independent registered public accounting firm. These estimates should not be viewed as a substitute for
the Company&#146;s full interim or annual financial statements. Accordingly, you should not place undue reliance on this preliminary data. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor and Media Contacts: </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>IR@serestherapeutics.com</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carlo Tanzi, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kendall Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ctanzi@kendallir.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mcrb-20250109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 9:27:09 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:mcrb="http://serestherapeutics.com/20250109"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://serestherapeutics.com/20250109"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mcrb-20250109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mcrb-20250109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mcrb-20250109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 9:27:09 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mcrb-20250109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 9:27:09 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mcrb-20250109.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46023014269392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001609809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  09,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SERES THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-4326290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">101 Cambridgepark Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">945-9626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MCRB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ "#@J6D O(UGN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ "#@J6IE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  (."I:=;^':%8$  "9$   &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ "#@J6I^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  (
M."I:EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  (."I:'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "#@J6B0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ "#@J6F60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d925391d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d925391d8k.htm">d925391d8k.htm</File>
    <File>mcrb-20250109.xsd</File>
    <File>mcrb-20250109_lab.xml</File>
    <File>mcrb-20250109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d925391d8k.htm": {
   "nsprefix": "mcrb",
   "nsuri": "http://serestherapeutics.com/20250109",
   "dts": {
    "inline": {
     "local": [
      "d925391d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "mcrb-20250109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mcrb-20250109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mcrb-20250109_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-01-09_to_2025-01-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d925391d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-01-09_to_2025-01-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d925391d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://serestherapeutics.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-25-004062-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-004062-xbrl.zip
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M(6'HR3=.>$^4\+E'WE7TO\+I#^^ 2\<GY7!91[75'56?W%&FV3HT0N8G0/K
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M( XPECSB4/_BWAW28,#(F1L1>.TT:O7EXWPI[B(,PM%T6"AD1':39T8!!D%
M2]@82A*I7S-OK[D\SDC,Q(W&4A<&8CW:7IB(#VU&U/2@@1%4'WIT,H$1L2!K
M3P"5_D*#F,J)X7]CGV!#\P;FS;)LVK)4ZYN0O>6B9$+"#AMPA6F Z K>/-WS
M.!6$51U 5+<_7W3.;BY^NVVWNOND?=4J+0@6GV$Z*IL@R^[%/043@=0PFIE0
M@5!%NB%S,63R" ](.U*D-82PA\E9D_<FYHO%_!ETV3F):,]GQ&6^C\@)4Z"%
M2D$_A]3SDF?;DYVI*WR?AHHUDP\/"PC)#]#0PJE4OK>4:U;L*)N5)!Z$<4G]
M?R\?9-;JWV,^(/MBS&3$7>I;HIJ)SA:RM:OKU4Z&.%<ZV\Q)V0Y1)F]#.F#%
MGF3T"V8[N<>:="Q "-:FCJ/9D^N19.2%Y 2FJ46%S$P V ZH-PN+9]7S 5!L
M3%0[<(4$UZAM43<"?]42<1#)24MXS_)]F"'%E$;$0BG&V&W.^3D.N&[FTSMP
MBDL1=>2MP_U4Q&>+;X6<3PY"#+T_<9_!NQX8HJ>[@RHFHYQB[7W]< %:L,3[
MY]+PEMZW;>;-U41[-D%KA=/J^V*]5CVL-BIK4'0+YN!H,];@J9Y_(V'ZKC8@
M&,0(7$@B?T'HH#RN0YQ'P1)G"X,#),*SQF[/N-?7T(_795)+C$9<J:^!)V@-
MB='>_UEVM#M=<C$*?3%A\M49DK>KY$J4IGS11@_^AQCR&T6D.KYY#B0]J&P$
M5-:/OEY0F:C8Z\:0*R# F>=)II3]<PEAG/,,]U\OG#H5A[3HJ">Y-V AE5_(
MN>3C!=#TZ0KZDH1IP<=K>2ON@F>0Y:!PFI)DEA#[JW(?=B :$5S+&X@!N-[*
M\.31'!9./Y\MXL>+.XVDO>=%7I9 -P*")/__>/BD@&M*GO<0$U2=^G+T^E7#
MUA6DW+7$PG12*$&0>$A]PNZ9&T>@I? UN"RF]K[FJ&<7>$R0R7MS+%G@5!^7
M2=^(99GFZ7YX=U1UWA\K((//PJ$(& DT2-M'".W'Z)<)!.X4Q!5$9KDI0#-T
M!N6>*=M'0+U#Y_W>?*[SR9'DI0#NW>#4GAT\-@JGC?I!L7%8/5QO;? 5>'LE
M(G(6AC[(+ C:<U+$FP&]GX0$"I$KG2*6Q#Y:+0<IZV-:.!@PCW31;9!+JB*[
MQ/.6*-[&2NLJ*0,H,&3N%[TF2,-0"C##&.OWQ#WI,5_<(<_P);)RM5[J=72M
M&Z3/?30G7(%MB5C@ <\C010?Q7Y$ R9BY4^( G54_8GNP580/2"7"5/L6J6<
M+C3$T(XD-)@D[_H0*H@[K(?I2([1KVHNE:3#IP8R&PU4TNAD&K',AT8SH=-:
M[KVP,";Y_GBA5UMF07^7/ )^838A#FS J)Z=,>X)X?<H\"H"R<I8V:K><-5X
M7Z\?SQO9%=Y^-L@G>=:29UO@F7UPA5-+&R!&EC@DS*S\=V(0EWKUP(KJS%H[
M+K'O.N])ZU.'5&N5$A1\3"#^)K^KY;<+IM@%:@>#SV#(P)KYVQ->YUL2WBEA
MH&E#F7G)76GAG3HM.M7$R$^%/+>+)!'QE:U5ZY62:7$O@ZG>M&%CVG C&5IR
MW'&M=\JA(Y;7_?X3D/':6E']EK1BI8@"!8MNAH2)Z*_R 6MHDE>L[O;V-JM+
MILTW;7H);6HK%3/Y(CI5>].IM72JQHKU77>S.F7;7%NG-AVA9?"C"868A& J
M7+K=% U $A_!;)>'0U_]NL[;3J,-YVC72%XLF>("Y7C5%<U;/-9H-@2[0^+Z
M5*F7631X*@E?FUZ2HGJ>]&3YM#L90;%=]4)K\R] L6TD,Z_L/E<M8,RZCU=?
MR1<! 5V$$4U=0=XA?74+SRO"=>/<)DZUIU7ZZ0G[:KUPBNA,H$<7[I=]$E))
MQM2/&?FN E+GD!"/@PX7;DU\E96E942QRFKT]!D4.2B<?FYU/GX=L]W>QH/'
M+*<G\I;@P2?MX)^%[6@=YK;"5@_!Z@($NZ+*HW^3+LHD^4SE%Q:1R\O6RVY!
M6+188P?VDR\@Y  ,Z0.*M -<G93<-,AM!Q[B?D9Z$^+J)8D1[M:X&S*]Y7!F
M'8 K L =8@?L=$ &4MQ%0PP?0EP;H(IXK,\#<QC!9&0K!V3^Z-/TQ%.-[**P
MOS\V:=FD-/0#8A+B.09<SUHS"*GVBFF&;+WS5FGOZT4D<QUDQEG:ZJIDX?1B
M,=%_>'?D-" Z?7AS1%+Y)UVW9:IN+VI^_T#4O%4BM?L/R">NMB\4=CZWWC4$
M4=9Z":(<"!WKQ8KI4D ONZJ&]Y%PO6!F;@M ^NB^_ EV?L>A:U2+ ,8';R0;
M<P7U0$%HX&(6F+HN'@[ PG@SB4>EI\QZFO=@H%G;I6F@F97JDA6&E/8;6]C]
MI]TP8%9W[1KOSLY"@738:$X@\:L,MNLQ8#E@._^.3E3!G!7;.1FF,! ";R&;
M[QKZWW$RF_ ^&UR[/J,2/?]0A[$[*Q;1-WMWQ,YL-O'C=>?\HE-L75]>GMUT
M+YK)AZ\YF^@X"].)1'\$29K/C<WO)FI';(3;="K.<;54J9;F=SYE6WNMC-]#
M@8J99H>IV(_TQJYKL$HVH0>VA7Q*S4Y+@!G$%R7R&+AQN D#?1V016=T]\'"
M22AYF[DO:Y^T [=$=M'*(6NJE>-6ZO.J5>=X#^"(BL%24C":N)M-@LFF8*9I
M$(!=1<':)Q3BDH$]/P'^.AA N]ABIBF]-0M:\/D(:"3!-5 UU#33'_2U3=0'
M_5.(<)(-$%P!XPF>0B;&'YPSE^'6)S.QFJ-G5M_7YE_["E]S RKUN$"_P] G
M&';UI1CI9E?BD"YHIW-PD*"0FR%.V.D1%PPFBB+4C3UP=7KX]G0&(W&(1Z=5
M"0E,^K'OZT@BF4N>>I:HO4F63HC\^K$,N!HBP1%-#7F/1Z31*#GHH306:L52
MXNEP>W@</..CMZ_LZH82?N?:2]A>>N!,KCD$_UPI12KQ(+UK3.,DFN!:-!4$
MC40* ?/#S&[JRU)I'T-@H#SBB1X#I PPQ4MFVN<^\^P$-8X [Q\*Q;2\Y;W_
MT9K8=A_91$=&.+-:E"V<T'0_/65T!R"%J+CW%T8EFK&,^)SVN&^ZTIW3B"@S
M*)!O(>W,>'9BT\-!1IC2&ZB0ABA1=M_1TOT:-D#(3D./<A;U[&.2B(7Z-#2[
MU[+L3Z8P"KI6YHRTFQ^#BEW0<CL,HQF)L.LQ1?0+C"00V9U1B .U*@$SXS#T
M]2H*#DH/4 \M6>.'04<1=5%=@*H,:LYHS9P89T3TR2L$;VX\<>-'I8KSS;KQ
M:^VO+O"J#?4*7OH,Y1[UEO;$&&1=+//:60]AO6X2&:WR=J"J/EH' 0X7="<4
M'!TLZ"6'/T]V@Z$/I7JBB!9;"A^,JG&(V' ((])>7*OW0.A=UQ"]#EC P#C@
MA7] 0<$9" /4 BN/LFUF ^V""] V8->:4:Q:_+G;NIWZI4_IKLC'3H!Z@#UT
M]&F,*O*?D3LT?1@;1O *)12W;H*4Z!-E8'@\YDKCLP/29^C]J=^+H:5]'08K
M%!3CL:=,P,QZ"*$IP!UD#I42+^O#O:(#S,\9Y "(2F!L.X:F@;NN]N5I&]H)
MJ F2"*]W#/H^'5E/B94Y+B8S,A0CAH<Q%,<=R%!=8"A.T:?!M'1,+LWF5,LT
M8X.G(P4[2W%;/+I?A3EWF+$.JM<E;@+N$B*/&'H-KD8X?NJF \Y*<0_HPL8L
MC<,1]6AE9/B$KB,!30('A#2$+Q[+;B 'S#U&HTEZOA ><)[1$=+2N%4%?4@1
M#X86H(F12+;F/LP]LT@QHA,":$Y3EYJN@-22JR_)\(V."C?=\=L#@J#CFF+1
M 851H5J"(''49*@#D@!?&%20&7C>?8+S$U-":K2@482X8Y@@"5Q]M:>9)IY
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MVK4:3@4+2D8]%(1"(43/M<*FR2II#W^FE2L&-1!C><$@5"0@;M\P<G$5H*_
M,RJ5,.R1TV'-(IW@,Y)O<R1QZN)9:0[-.>V\(G+P84X*US9)H;1DMM+N@EJ%
M(@!W8 !14SVPF< K6SV\ 6"#J7VL&"(Q?NO-_%%0?NM\R8BML8UZXNYI_@63
MK=V>Z>H*((S4H9YZ7(I&8>"$(<]X$B;H/]<QD-GD(^B)O!<F0:@B)%-^%74P
MQ</]X9$/B0EF/M:3*0PSL=I#"4*-$@3P=C>+@%+S\KN#+E9]FEU)?85F5F>P
M&CV H8>RA!3!V!IC!!O5U9(F*K= 30[ZD[8,VF##EP]3+9GKZ-TU3?& 08K5
ME:BQ+"&E]T32[*!T54(17@TD<,&OTXO]@ND)=?OPQ$=2EJGE*-"S;DFOGED<
M8)?:%LX72J6W,R>H<S0/0PQMAH=]C4SJ7*LK&H2QE$$XZ>RM+?<>;47RY>ZX
MH*O'UG)LI\RY=K3)AWL5M\/C<=5.#SR&Q%N&17[Y2DW=@T%1?\EXVI*F;W2\
MG[_*Z1[OVG7N(V2?7Y"'IPID;^G<A 2(1J8:4D,=OIP<VNLSGER@H4X:2'S
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M:M4Y_\)I*IZB.YV.8*JRG0X(M!HB)L]-K"N<+QI.]#7$@&A+] U17EO^[L7
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MSZ'KHF,/  B-**I:&P=M/U[H(HS)CISZ7W%?BMA?Q=DH/L@2,A:!VJ*^HX[
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MBD*058*\%-)G?"W:,'S(9^NEO.-2;>G?.Y'OHMEO7U![_@-02P,$%     @
M"#@J6A50I@2X!   ABH  !4   !M8W)B+3(P,C4P,3 Y7W!R92YX;6S5FEV/
MXC84AN]7VO_@IC>MU!#"S'0+&F9%F9D5ZGR)8=NJ-RN3',"J8T>V&>#?]SC@
M%8&P"]-M%<_% ([?X_><QS&)R>7[9<;)"RC-I.@&<:,9$!")3)F8=H.Y#JE.
M& N(-E2DE$L!W6 %.GA_]?;-Y7=A2*YO!P\D)#-C<MV)HL5BT4@G3&C)YP9#
MZD8BLXB$H>O?'WTDOZ^'ZY A<* :2$:U 45^G3.>=EK-UGD<MUJ->%NF@-IX
M)*4&.B2.XF:$'2](N]-ZUVFV2>^>W!11!!FQ#+:E,E\I-IT9\D/R(RE$UU((
MX!Q6Y)8)*A)&.7EVCG\B Y$T2(]S,K0RC38UJ!=(&YNHG(F_._;?V)HG;]\0
M_,,Z"EVT=@-;C4TQEF/%&U)-T6WS+'*B8%NSW!,MS@I)W&ZWH^)HN;]F5;UQ
M@#CZ\_[N.9E!1D-D@,R2G:'036H^J[?-743K@ZZ_9AU=1+J325'Z(](B!WO8
M3Z'K%MJF,&Z%9W%CJ=/@R@ZYKJJ2'(8P(?;UXW#P>4P$ -K,0-$<$%.RGE?%
M%&C&S79DZ%(*F:TB*XRN93+/0!CWVA/IC3#,K 9B(E56I!.0HK*=F8))-\@2
M-0Y=-&OJ^R$&^G1*(+/*\>30+,LY!"3:2BI'[R@N>M]A0TD 2P,BA=2%L0G\
MEVE?K?EN)K%,2F5PIW$!3T/2F,J7* 5F1SRW;VR-SHOZX(=/?8DK1V^LC:*)
M*=>!VUDCE6OD= R\&U2(HF]IJ(=IIS;U6TZGQQK:$94-;;/KJ:04DJK$A<.W
M)7#[9\"F1Y13A?'"9(9KG5-/E,PJB[,9358:E2H%U0UPI<0S/R"Y8E(A;&P)
MR%RC%YE;UY3;8S !I2"]6Z=]T&5A$5=1#47/;XQG/1O[F(&B?("S?OD;K([%
M=$!<7UP'##ML9]Y@<^O)",MX+*VRIKZ0RCX=FPOOV#P!>L7E/KW&"Z13(>V(
MZT]KQ[##]K,WV-9KPQ"FS"8JS /-CJ96K:TOM&J_CMD[SYCAS8%4N51%:9^Q
MPM"7<USB5WV9GHCP*Z'J3O0K]AW@7SP#?,LX/,RS,:C3:&[KZHYNVZOCU/:,
MTX@N!RF6@4W8^@;U-= .!JD[P8/&-SC/FI[A[*4I%EEO7O V&>+34%8&J#O&
M2M,.8>PGPCZ^?50CN1"O K@M]P3?MF4'S[>[\DTJQ??XHWI2\H79W</7$-R+
MX0G&/=^.I3^WZJ5\GJ0VE/_%\M,O3:LC>,)QQ[6C>.X-1;N>]!304[B5-?4E
M5?;IV/BSX6)_#N%/,RE.O$G8U]67T;Y7Q\F?'98_T)\!T9=9-A>;:V1]+*P#
MXOH2.V#88?-GD^59<I8PP\3T'K^,%;/6CF-6I:POL"JWCI8_.R9/"NR4 [Q:
M*C;1[2^9ZG$R.7Y9_%*$^M+[DFM'T9_]E)UL!EK/0?U[EA5QO"%:X7W#]=R?
MC95G2.;68MP:CYCA1U]*[NOJRVW?J^/DS^[)2%'[O-7S*AO+H[_N=D3U);1C
MU.'Q9W_$3;&;93*C8@JG_%97K:TOK&J_CIEO^R W&:@ISKT/2B[,#-?WG(H3
MGS<Y$**^!+]HVX'\'[9"+J.]TMQA@WU^<GW$_K-/ V++/U!+ 0(4 Q0    (
M  @X*EKUY5#RF1@  (&&   .              "  0    !D.3(U,SDQ9#AK
M+FAT;5!+ 0(4 Q0    (  @X*EJI'_Y ;!@  '-6   1              "
M <48  !D.3(U,SDQ9&5X.3DQ+FAT;5!+ 0(4 Q0    (  @X*EH"$M+)0P,
M %L+   1              "  6 Q  !M8W)B+3(P,C4P,3 Y+GAS9%!+ 0(4
M Q0    (  @X*EI<=0P&6P8  +Y#   5              "  =(T  !M8W)B
M+3(P,C4P,3 Y7VQA8BYX;6Q02P$"% ,4    "  (."I:%5"F!+@$  "&*@
M%0              @ %@.P  ;6-R8BTR,#(U,#$P.5]P<F4N>&UL4$L%!@
0   %  4 0 $  $M       $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d925391d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mcrb-20250109.xsd" xlink:type="simple"/>
    <context id="duration_2025-01-09_to_2025-01-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001609809</identifier>
        </entity>
        <period>
            <startDate>2025-01-09</startDate>
            <endDate>2025-01-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-297">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-01-09_to_2025-01-09"
      id="Hidden_dei_EntityCentralIndexKey">0001609809</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-308">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-309">2025-01-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-310">SERES THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-311">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-312">001-37465</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-313">27-4326290</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-314">101 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-315">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-316">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-317">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-318">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-319">945-9626</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-320">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-321">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-322">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-323">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-324">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-325">MCRB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-326">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-327">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
